focus -WSS

focus

author：hotspot 2025-08-26 23:48:46 - browse：624

intarcia implant. -- health tech coverage from STAT — The matchstick-sized, implantable device from Intarcia Therapeutics releases a steady, continuous, and low-dose stream of a drug for diabetes. Stuart Isett/Fortune Brainstorm Health

An advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA rejected said implant not once, but twice.

Intarcia called for the panel meeting because of those two rejections, seeking outside input on the FDA’s decision. FDA then granted Intarcia’s request. The agency is not bound to advisory panel decisions, though it tends to follow their advice.

Intarcia started developing its lead therapy, a small, skinny bar implanted under the skin, for type 2 diabetes patients in 2016. The implant delivers a glucose-controlling medicine called exenatide, a member of the GLP-1 drugs that have taken the diabetes and obesity markets by storm. Intarcia’s implant continuously administers the drug over six months, with the goal of improving patient adherence compared to Eli Lilly and Novo Nordisk’s weekly GLP-1 shots.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： CDC: Cases of alpha

knowledge

WSS

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

H5N1 bird flu found in pasteurized milk: what we know

After traumatic brain injury, life support decisions can use more time

Biden to sign 'historic' executive order on how US military handles sexual assault cases

Melinda French Gates resigns from Gates Foundation

H5N1 bird flu virus started spreading in cows in Texas in December

entertainment

focus

hotspot

Drug repurposing or repositioning? The language matters

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

DIEP, the 'gold standard' of breast reconstruction, is under threat

'Hero' Louisville officer shot in head at mass shooting discharged over 3 months later

The cancer drug shortage isn’t new — and neither are the solutions

Medical bills so high, Medicare adding extra digits to claim forms

Moonlake's readout produced a cash windfall. Risks remain

Exact Sciences stock tumbles despite strong cancer detection sales

In age of alternative facts, a scholarly course on calling out crap

Cue Health's Covid

explore

Biden announces an advanced cancer research initiative

Ford recalls 870K F

Hospitals, health systems can help patients avoid medical debt

'Hero' Louisville officer shot in head at mass shooting discharged over 3 months later

MassMutual is introducing free genetic testing for members

‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart

entertainment

knowledge

leisure time

explore